12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

ForSight Vision4 Inc., Roche deal

Roche's Genentech Inc. unit said it will make an undisclosed milestone payment to ForSight under a 2010 deal granting Genentech exclusive, worldwide rights to develop and commercialize ForSight's implantable ocular device to deliver anti- VEGF-A treatments for ophthalmic disorders. Genentech said the milestone, the first under the deal, was triggered by its decision to submit an IND for the refillable drug port delivery system (PDS) to deliver Lucentis ranibizumab over a period of months....

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >